These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36437108)

  • 1. Design, synthesis, and structure-activity relationships of diindolylmethane derivatives as cannabinoid CB
    Mahardhika AB; Ressemann A; Kremers SE; Gregório Castanheira MS; Schoeder CT; Müller CE; Pillaiyar T
    Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200493. PubMed ID: 36437108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Cannabinoid Receptor 2 (CB2) Low Lipophilicity Agonists Produce Distinct cAMP and Arrestin Signalling Kinetics without Bias.
    Sharma R; Singh S; Whiting ZM; Molitor M; Vernall AJ; Grimsey NL
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
    Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M
    Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway.
    Dhopeshwarkar A; Mackie K
    J Pharmacol Exp Ther; 2016 Aug; 358(2):342-51. PubMed ID: 27194477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB
    Grafinger KE; Cannaert A; Ametovski A; Sparkes E; Cairns E; Banister SD; Auwärter V; Stove CP
    Drug Test Anal; 2021 Jul; 13(7):1402-1411. PubMed ID: 33769699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of structurally novel G protein biased CB
    Ford BM; Franks LN; Tai S; Fantegrossi WE; Stahl EL; Berquist MD; Cabanlong CV; Wilson CD; Penthala NR; Crooks PA; Prather PL
    Pharmacol Res; 2017 Nov; 125(Pt B):161-177. PubMed ID: 28838808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
    Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
    Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diindolylmethane Derivatives: Potent Agonists of the Immunostimulatory Orphan G Protein-Coupled Receptor GPR84.
    Pillaiyar T; Köse M; Sylvester K; Weighardt H; Thimm D; Borges G; Förster I; von Kügelgen I; Müller CE
    J Med Chem; 2017 May; 60(9):3636-3655. PubMed ID: 28406627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity?
    Ametovski A; Cairns EA; Grafinger KE; Cannaert A; Deventer MH; Chen S; Wu X; Shepperson CE; Lai F; Ellison R; Gerona R; Blakey K; Kevin R; McGregor IS; Hibbs DE; Glass M; Stove C; Auwärter V; Banister SD
    ACS Chem Neurosci; 2021 Nov; 12(21):4020-4036. PubMed ID: 34676751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring Stereochemical and Conformational Requirements at Cannabinoid Receptors for Synthetic Cannabinoids Related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA.
    Ametovski A; Macdonald C; Manning JJ; Haneef SAS; Santiago M; Martin L; Sparkes E; Reckers A; Gerona RR; Connor M; Glass M; Banister SD
    ACS Chem Neurosci; 2020 Nov; 11(21):3672-3682. PubMed ID: 33054155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB
    Ryalls B; Patel M; Sparkes E; Banister SD; Finlay DB; Glass M
    Biochem Pharmacol; 2024 Apr; 222():116052. PubMed ID: 38354957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.
    Xu JJ; Diaz P; Astruc-Diaz F; Craig S; Munoz E; Naguib M
    Anesth Analg; 2010 Jul; 111(1):99-109. PubMed ID: 20522703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists.
    Dhopeshwarkar A; Murataeva N; Makriyannis A; Straiker A; Mackie K
    J Pharmacol Exp Ther; 2017 Feb; 360(2):300-311. PubMed ID: 27927913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Motifs in Natural Products as Useful Scaffolds to Obtain Novel Benzo[
    Cho AYH; Chung H; Romero-Parra J; Kumar P; Allarà M; Ligresti A; Gallardo-Garrido C; Pessoa-Mahana H; Faúndez M; Pessoa-Mahana CD
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 7-Azaindolequinuclidinones (7-AIQD): A novel class of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor ligands.
    Penthala NR; Shoeib A; Dachavaram SS; Cabanlong CV; Yang J; Zhan CG; Prather PL; Crooks PA
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127501. PubMed ID: 32882418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 4-(1,2,4-Oxadiazol-5-yl)azepan-2-one Derivatives as a New Class of Cannabinoid Type 2 Receptor Agonists for the Treatment of Inflammatory Pain.
    Nan J; Liu J; Lin G; Zhang S; Xia A; Zhou P; Zhou Y; Zhang J; Zhao J; Zhang S; Huang C; Wang Y; Hu Q; Chen J; Xiang M; Yang X; Yang S
    J Med Chem; 2023 Mar; 66(5):3460-3483. PubMed ID: 36821347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of an activity-based receptor bioassay to investigate the in vitro activity of selected indole- and indazole-3-carboxamide-based synthetic cannabinoids at CB1 and CB2 receptors.
    Noble C; Cannaert A; Linnet K; Stove CP
    Drug Test Anal; 2019 Mar; 11(3):501-511. PubMed ID: 30280499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indol-3-yl-tetramethylcyclopropyl ketones: effects of indole ring substitution on CB2 cannabinoid receptor activity.
    Frost JM; Dart MJ; Tietje KR; Garrison TR; Grayson GK; Daza AV; El-Kouhen OF; Miller LN; Li L; Yao BB; Hsieh GC; Pai M; Zhu CZ; Chandran P; Meyer MD
    J Med Chem; 2008 Mar; 51(6):1904-12. PubMed ID: 18311894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabinoid 2 receptor- and beta Arrestin 2-dependent upregulation of serotonin 2A receptors.
    Franklin JM; Vasiljevik T; Prisinzano TE; Carrasco GA
    Eur Neuropsychopharmacol; 2013 Jul; 23(7):760-7. PubMed ID: 22841827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles.
    Wiley JL; Marusich JA; Lefever TW; Grabenauer M; Moore KN; Thomas BF
    Neuropharmacology; 2013 Dec; 75():145-54. PubMed ID: 23916483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.